Business
Metagenomi Announces Publication in Nature Communications on Large Gene Integration Advances Using Novel, Compact CRISPR-associated transposase (CAST) Systems
Achieved targeted integration of a large, therapeutically relevant gene into the genome of human cells with compact CAST system AI-driven metagenomics platform facilitated discovery of CAST system with activity in human cells Expression of the compact CAST system from a single 'all-in-one' mRNA design represents a first-in-class approach to simplifying delivery for therapeutic applications Additional updates on further advancements in novel large gene integration technology anticipated in 2025 E
About this update from Metagenomi Therapeutics, Inc.
[{"type":"image","alt":"Metagenomi, Inc.","displaySize":"","headline":null,"caption":"Metagenomi, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":120,"url":"https://media.zenfs.com/en/globenewswire.com/f9f4f8ce15a62dc256eccc8b2b88fc5f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Ld3K1HIDljOFxzdNkgn1rg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f9f4f8ce15a62dc256eccc8b2b88fc5f","width":300,"height":120}},"lazy":false},{"type":"text","content":"Achieved targeted integration of a large, therapeutically relevant gene into the genome of human cells with compact CAST system","length":127,"tagName":"p"},{"type":"text","content":"AI-driven metagenomics platform facilitated discovery of CAST system with activity in human cells","length":97,"tagName":"p"},{"type":"text","content":"Expression of the compact CAST system from a single 'all-in-one' mRNA design represents a first-in-class approach to simplifying delivery for therapeutic applications","length":174,"tagName":"p"},{"type":"text","content":"Additional updates on further advancements in novel large gene integration technology anticipated in 2025","length":105,"tagName":"p"},{"type":"text","content":"EMERYVILLE, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced a publication in the journal Nature Communications describing its novel, compact CAST system for large, targeted gene integration into the human genome.","length":401,"tagName":"p"},{"type":"text","content":"Metagenomi’s CAST systems are a potential solution for development of curative genetic medicines, as these natural systems perform a task critical to the field of gene editing: precise, programmable integration of large gene cargoes. This technology has the potential to address a large collection of complex genetic diseases caused by any loss of function mutations, such as Wilson’s disease, cystic fibrosis, and Duchenne Muscular Dystrophy. The newly published data demonstrates a first-in-class approach to precisely integrating therapeutic genes into the human genome, building on prior findings that established the potential of these systems.","...